ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing
ZEISS Medical Technology and Envision Health Technologies will collaborate to advance the next generation of patient-accessible, software-driven visual function testing while maintaining a science-first approach to glaucoma care. JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technology, one of the world's leading medical technology companies, today announced a strategic collaboration...
Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific
DA NANG, Vietnam, June 18, 2026 /PRNewswire/ -- Gene Solutions announced the successful conclusion of K-CONNECT Summit 2026, a regional scientific forum that brought together leading oncology experts, clinicians, researchers and healthcare stakeholders to discuss how Artificial Intelligence (AI) and multi-omics are reshaping cancer care across Asia-Pacific. Held in Da Nang, Vietnam, the hybrid summit...
Navigating Primary Biliary Cholangitis in Singapore: Addressing the Diagnostic Gap and the Next-Generation Therapies
90% Female Prevalence: PBC is a critical women's health issue, yet symptoms like crushing fatigue and relentless itching are frequently misdiagnosed as menopause or stress. 30-Year Innovation Gap: This new class of therapy is the first major breakthrough in three decades for the 40% of patients who do not respond to traditional treatments. Beyond the Blood Test: While 80% of...
WuXi Biologics’ Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the fourth time the facility has successfully received EMA...
AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial
SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech, today announced positive results from HistoIndex's AI-based quantitative analysis of liver biopsy samples from the Phase 2 clinical trial of zabopegdutide (DD01) - an investigational treatment for metabolic dysfunction-associated steatohepatitis (MASH). Zabopegdutide is a...
ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units
JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today that the company held a signing ceremony with the Aier Eye Hospital Group, entering into a strategic agreement for the purchase and installation of 25 ZEISS VISUMAX 800 femtosecond lasers across multiple Aier Eye Hospital locations. The signing ceremony...
Tinnitus Quest Builds Momentum with Oxford Research Study, New Funding Call, and Second Tinnitus Hackathon
OXFORD, England, June 18, 2026 /PRNewswire/ -- Tinnitus Quest, an international patient-driven nonprofit dedicated to accelerating research into treatments to silence tinnitus, today announced the launch of a new round of research funding aimed at uncovering bold, innovative ideas to silence tinnitus. Hazel Goedhart, co-founder of Tinnitus Quest, announces our...
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969. ISM8969 is a potentially...
FiberSense Continuous Glucose Monitoring (CGM) System obtains CE mark as commercial launch preparations begin
Major regulatory milestone paves the way for commercialization and marks first step toward broader CxM biomarker sensing strategy BASEL, Switzerland, June 17, 2026 /PRNewswire/ -- FiberSense AG ("FiberSense") today announced that the FiberSense Continuous Glucose Monitoring (CGM) System has obtained CE marking under Regulation (EU) 2017/745 as a Class IIb medical...
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase 2 clinical proof-of-concept trial (NOVA). The study is evaluating vipoglanstat, a novel, non-hormonal, non-opioid drug candidate for the treatment of endometriosis. This...
